Where I see patients (1)
My reviews
Selected research
-
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Cancer
-
Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck.
Head & neck
-
The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembrolizumab.
Head & neck
Clinical trials
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Intratumoral CD3+ T-cells will be identified by immunohistochemistry in pre- and post-treatment tumor specimens. The analysis population for the primary outcome will be all patients who received at least 2 weeks of neoadjuvant the...
Recruiting
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma ...
TEAE's are defined as Adverse Events (AEs) with onset after date-time of first dose, or medical conditions present prior to the start of IMP but increased in severity or relationship after date-time of first dose of IMP.
Recruiting
4.9